What is Pacific Biosciences of California, Inc.'s (PACB) StockRank?

MoatMap's StockRank for Pacific Biosciences of California, Inc. (PACB) is 16/100, with a Strong Sell signal. This is a composite score combining Quality (23), Value (46), and Momentum (27) factor ranks across MoatMap's universe of 25,000+ stocks.

Does Pacific Biosciences of California, Inc. have an economic moat?

Pacific Biosciences of California, Inc. (PACB) has a Quality factor score of 23/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Pacific Biosciences of California, Inc. a buy, hold, or sell?

MoatMap's current signal for Pacific Biosciences of California, Inc. (PACB) is Strong Sell, based on a StockRank of 16/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Pacific Biosciences of California, Inc. in?

Pacific Biosciences of California, Inc. (PACB) operates in the Healthcare sector, specifically the Medical Devices industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

PACB

Strong SellSinker

Pacific Biosciences of California, Inc. · Healthcare · United States · $435M · Avg Vol: $9M/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

-929.3%

D/E

131.3x

Dividend %

—

COMPANY DESCRIPTION

Pacific Biosciences of California, Inc. develops and markets advanced DNA sequencing systems utilizing its proprietary Single Molecule, Real-Time (SMRT) technology. The company holds a strong position in the long-read sequencing market, providing high-fidelity data essential for complex genomic research and clinical applications. Its innovative technology offers a competitive moat by enabling more comprehensive analysis compared to traditional short-read methods.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM	2026E	2027E	Fwd CAGR
Revenue	128.3M	200.5M	154.0M	160.0M	7.6%	159.3M	158.2M	184.0M	7.2%
EPS	-1.40	-1.21	-1.12	-1.82	—	-0.42	-0.51	-0.41	—
Shares	226.5M	267.7M	294.4M	302.0M	+33.3%	310.8M	—	—	—
Debt	948.5M	933.9M	672.4M	702.4M	-9.5%	709.1M	—	—	—
Equity	562.9M	701.3M	506.6M	5.3M	-78.8%	—	—	—	—
Op CF	-263.2M	-259.2M	-206.1M	-111.2M	—	-118.0M	—	—	—
Inv CF	116.1M	4.6M	124.0M	115.4M	—	—	—	—	—
Fin CF	9.6M	108.9M	-43.0M	3.4M	—	—	—	—	—

Loading 1Y...

PRICE (1Y)-6.1%

SMA 50SMA 200

$1.32

RSI (14)

52.4

52W High

$2.73

From 52W High

0.5%

SCORE BREAKDOWN

Quality

ROIC

-17.3%30.8

ROE

-929.3%25.0

GP/Assets

6.0%19.8

Op. Margin

-114.4%16.3

FCF/Assets

-15.2%24.8

Piotroski

316.1

Int. Cover

-16.8x18.3

D/E Ratio

131.32x0.1

Current Ratio

4.92x71.7

Value

P/E (TTM)

—N/A

EV/EBITDA

4.5x93.9

P/FCF

—N/A

P/B

-12.6x25.0

P/S

2.6x60.9

Div Yield

—N/A

Momentum

52W High %

48%21.0

RS 6M

-18%43.7

SMA 50/200

0.85x22.8

EPS Rev 4W

-2.7%18.3

EPS Rev 12W

-2.1%26.7

EPS Improve

+4%24.4

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$435M

P/E (Forward)

-3.3x

Gross Margin

29.4%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PACB are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
PACB	Pacific Biosciences of California, Inc.(you)	$435M	16	Strong Sell
MOBI	Mobia Medical, Inc.	$378M	15	Strong Sell
CLPT	ClearPoint Neuro, Inc.	$474M	10	Strong Sell
CATX	Perspective Therapeutics, Inc.	$355M	12	Strong Sell
CV	CapsoVision, Inc.	$297M	13	Strong Sell
RXST	RxSight, Inc.	$293M	19	Strong Sell
TLSI	TriSalus Life Sciences, Inc.	$297M	20	Strong Sell
IMR.AX	Imricor Medical Systems, Inc.	$506M	6	Strong Sell
OFIX	Orthofix Medical Inc.	$392M	27	Sell
LAB	Standard BioTools Inc.	$252M	18	Strong Sell

Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%

Pacific Biosciences of California, Inc. (PACB): Stock Score Summary

Pacific Biosciences of California, Inc. (PACB) has a MoatMap StockRank of 16/100 based on Quality (23/100), Value (46/100), and Momentum (27/100) factor scores. The current signal is STRONG SELL.

Key Financial Metrics

Price	$1.32
Market Cap	$435M
P/E (Forward)	-3.33
Price/Book	-12.62
Return on Equity	-929.3%
Return on Invested Capital	-17.3%
Debt/Equity	131.32x
Gross Margin	29.4%
Operating Margin	-114.4%
Revenue Growth	-1.9%
Free Cash Flow	$-119M

Pacific Biosciences of California, Inc. operates in the Medical Devices industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Pacific Biosciences of California, Inc.’s (PACB) StockRank?: MoatMap’s StockRank for Pacific Biosciences of California, Inc. (PACB) is 16/100, with a Strong Sell signal. It is a composite of Quality (23), Value (46), and Momentum (27) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does Pacific Biosciences of California, Inc. have an economic moat?: Pacific Biosciences of California, Inc. (PACB) has a Quality factor score of 23/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Pacific Biosciences of California, Inc. a buy, hold, or sell?: MoatMap’s current signal for Pacific Biosciences of California, Inc. (PACB) is Strong Sell, based on a StockRank of 16/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Pacific Biosciences of California, Inc. in?: Pacific Biosciences of California, Inc. (PACB) operates in the Healthcare sector, specifically the Medical Devices industry (United States).